Platelet-activating factor (PAF), an ether phospholipid, is recognized as being an effective and potent modulator of secretory processes in various cell types (Snyder, 1982). Physio-pathological studies have shown that PAF participates in inflammatory processes and in immune functions (Braquet et al., Res. Pharmacol. Rev., 1987). In the central nervous system, PAF has been isolated from bovine cerebral tissues (Tokumura and Tsukatani, 1986) and Francescangeli and Goracci (1989) demonstrated that rat brain synthesizes PAF under resting conditions. Moreover, Kumar et al. (1988) reported that the rat cerebrum produces PAF in response to convulsive stimuli.

We studied PGE2 specific binding sites in human myometrial microsomes prepared from uterine specimens obtained by hysterectomy (women between 38 and 55 years of age). Competition experiments showed that the potency order for various prostaglandins (PGs) was: PGE2 > or = PGE1 >> PGF2 alpha > Iloprost > or = Carbacyclin >> ZK 110841 (PDG2 analogue). These relative affinities indicated that the receptor was of the EP type. In kinetic experiments GTP, GppNHp and GTP gamma S increased the rate of PGE2 binding (steady state was reached more rapidly in the presence of nucleotides) but maximal specific binding was not significantly different. Complete dissociation could not be obtained, even in the presence of GTP. Only 50% of maximal binding was readily dissociable. The dissociation rate was 4.56.10(-4) sec-1 (half time of about 660 sec) and in the presence of GTP analogues it was slightly increased (k-1 = 7.16 10(-4) sec-1, half time 420 sec.). Scatchard analysis of saturation curves showed an increase in ligand receptor affinity in the presence of GTP or nucleotide analogues: the Kd shifted from 9.66 +/- 2.8.10(-9) M to 4.96 +/- 1.25.10(-9) M, but the number of binding sites did not change significantly (310 +/- 37 to 350 +/- 17 fmol/mgP). The effect of GTP was observed at a concentration of 5.10(-4)M. GppNHp and GTP gamma S were effective at 1.10(-5) M. Pretreatment of myometrial membranes with pertussis or cholera toxins had no effect on PGE2 binding to membrane sites. Our conclusion is that GTP induced conversion of a population of low affinity sites into a population of higher affinity sites. This effect of guanine nucleotides was described in adipocytes and kidney medulla. Competition studies with PGE2 analogues (sulprostone, 17-phenyl-omega-trinor PGE2, M&B 28,767, misoprostol, butaprost) showed that this receptor mediates a contractile response and is probably an EP3 subtype.

We investigated the effects of prostaglandins on cyclic AMP (cAMP) levels and on the activity of the rate-limiting enzyme of melatonin biosynthesis, arylalkylamine-N-acetyltransferase (NAT). The study was performed on primary cultures of dispersed chick pineal cells. Prostaglandin E, (PGE,) increased cAMP levels 2-fold and this stimulation went up to 4-fold in the presence of a phosphodiesterase inhibitor. The PGE,- evoked increase in cAMP levels did not desensitize over 6 h. The potency order of a series of prostaglandins to increase cAMP levels (PGE(1) PGE(1) >PGA2>PGD(2) ≃PGF(2) α) agreed with the pharmacological profile of the adenylate cyclase-coupled prostaglandin receptor. Inhibition of endogenous prostaglandin synthesis by two cyclooxygenase inhibitors (indomethacin and aspirin) caused a 30% decrease in cAMP levels. This effect was completely reversed by the addition of exogenous PGE(1) or PGE(2) . Indomethacin and aspirin also caused a 50% decrease in NAT activity. Prostaglandins of the E series increased NAT activity up to 2-fold above basal level and restored NAT activity after inhibition by indomethacin or aspirin. These results are the first illustration of a role for prostaglandins in chick pineal cells. The correlations observed between cAMP levels and NAT activity suggest that the regulation of NAT activity by prostaglandins of the E series might be mediated by changes in cAMP concentration.

We have previously shown that exogenous (1 to 5 nmol i.c.v.) PAF induces a rapid increase in plasma ACTH and beta endorphin followed by an increase in plasma corticosterone in conscious rats. The stimulatory action of PAF on the secretion of hypothalamic-pituitary-adrenal (HPA) axis products is mediated at least partly by stimulating hypothalamic CRF release. In addition rat hypothalamic membranes have two populations of specific PAF binding sites. In order to clarify the mode of PAF action on the stress-related hormones, we have now investigated the effect of two PAF antagonists, BN 50739 and RP 52770, on basal and PAF-induced ACTH and corticosterone secretion by conscious rats and on PAF specific binding to rat hypothalamic membranes. The role of PAF as a mediator of neuroendocrine secretion in response to acute stress was examined by determining the effect of PAF antagonists on ether-stress inducing HPA activity. We have also investigated their effect on IL 1-induced HPA activity. The ability of BN 50739 and RP 52770 to displace 3H PAF from its hypothalamic binding sites was correlated with their ability to alter basal hormone secretion and to counteract the PAF-stimulated secretion of HPA axis hormones in vivo (P less than 0.05 by ANOVA). Pretreatment with BN 50739. (50 nmol i.c.v.) did not alter ACTH response to a 1 min ether exposure or to IL1 beta injection (2 nmol i.c.v.). In contrast, RP 52770 (55 nmol i.c.v.) significantly inhibited the ether stress-induced ACTH and corticosterone production by 50% (P less than 0.05). In parallel, pretreatment with RP 52770 (55 nmol i.c.v.) caused a significant inhibition of IL1 beta-induced ACTH secretion. These results suggest that PAF acts, in vivo, on ACTH and corticosterone secretion, through a centrally mediated CRF dependent mechanism involving PAF receptor sites. Additionally, the data also indicate that PAF could have a central role in mediating basal and stress-induced ACTH secretion and that IL 1-induced HPA secretion may be mediated at least in part through the production of PAF.

A radioreceptor assay (RRA) was developed using rabbit platelet membrane preparations to quantify platelet-activating factor (PAF) and lyso-PAF, the deacylated derivative of PAF, in a variety of tissues and biological fluids. We examined PAF and lyso-PAF levels in different rat brain areas with regard to the many proven and postulated actions of PAF in brain functions. Human saliva was selected to check the validity of this RRA. The samples were extracted with methanol/chloroform/water and purified by high-performance liquid chromatography on a 5-microns Nucleosil Si column (overall recovery: 78%). Sample extracts were acetylated before chromatography to assay lyso-PAF. PAF itself was assayed in non-aceylated samples. A competitive binding assay was performed using aliquots of platelet membrane preparation and tritiated PAF. The minimum detectable amount of PAF was 144 pg per tube and the receptor was highly specific for PAF. In human saliva, we confirm the presence of PAF and lyso-PAF within the range expected. Moreover there was a good correlation between the RRA and the aggregation assay (r = 0.976). A defined cocktail of protease inhibitors allowed storage of platelet membrane preparations for at least 3 months at -20 degrees C with no change in binding properties. In the brain we observed the prevalent presence of lyso-PAF and large variations in PAF and lyso-PAF concentrations between the different brain areas analyzed. PAF was undetectable in the hypothalamus but the lyso-PAF concentration was 2.5 micrograms/g wet tissue. The PAF concentration in the cortex varied from 0 to 16 ng/g wet tissue while that of lyso-PAF was 0.7 micrograms/g wet tissue. Moreover the amount of lyso-PAF varied between the different brain areas analyzed. The hippocampus contained the highest amount (7 micrograms/g wet tissue), and relatively high levels were found in the hypothalamus, medulla oblongata and corpus striatum. The cerebellum and cortex contained the lowest levels of lyso-PAF. These findings show that PAF is present in the central nervous system mainly in its inactive form, lyso-PAF, and suggest that its effects as a modulator of brain function may be dependent on deacetylation, rather than synthesis.

Arachidonate 12-lipoxygenase is a dioxygenase which incorporates one molecule of oxygen into arachidonic acid regiospecifically and stereospecifically, and produces 12S-hydroperoxy-5,8,10,14-eicosatetraenoic acid (Figure 1). Since the enzyme was found in platelets as the first mammalian lipoxygenase (1,2), the 12-lipoxygenase has been found in a variety of tissues of a number of animal species (3,4). In addition to 12-lipoxygenase, several more lipoxygenases have been found in mammalian tissues. It is well known that the leukotriene synthesis is initiated by 5-lipoxygenase and the biosynthesis of prostaglandin and thromboxane by cyclooxygenase. These compounds have specific biological activities which regulate the functions of various animal tissues, and their biological functions have been generalized for a variety of animal species and tissues. However, no bioactive compound with such a general function has so far been found in the 12-lipoxygenase pathway of arachidonate metabolism (5).

The amounts of prostaglandin E2 formed in vitro by the median eminences of adult male rats were greater than those produced by the median eminences of immature, 22 day-old rats. However, the amount of leukotriene C4 produced by the adult rat median eminences was lower than that produced by the immature rat median eminences. Analysis of the prostaglandin E2 binding parameters of hypothalamic P2 membrane fractions indicates that there are two binding components, one high affinity (RH) and one low affinity (RL) in both adult and immature rats. The maximal binding capacity of RH from adult rat membranes was significantly lower than that of immature rat membranes, correlating with greater prostaglandin E2 production by the adult rat median eminence. Only one leukotriene C4 binding site was detected in both adult and immature rat membranes. Exogenous prostaglandin E2 and leukotriene C4 both stimulated, the release of luteinizing hormone-releasing hormone to the same extent from both the adult and immature median eminences.

To investigate whether platelet-activating factor (PAF) exerts an indirect action on immune cells by altering the secretion of hypothalamic-pituitary-adrenal (HPA) axis products, the effects of intracerebroventricular (i.c.v.) PAF on adrenocorticotropic hormone (ACTH), beta-endorphin and corticosterone blood levels were examined in adult male rats. Hormones were radioimmunoassayed on blood samples from conscious or ether-anesthetized rats after i.c.v. injection of PAF or vehicle into the left lateral ventricle. PAF induced significant increases in these stress-related hormones under both, basal and ether-induced stress conditions. The analysis of the time course response to PAF of hormone release into the blood of unrestrained rats revealed that: i.c.v. injection of 5.4 nmol PAF resulted in rapid increases in ACTH and beta-endorphin, at the latest within 15 min after the onset of injection. The maximal response of both hormones was reached within 45 min after the onset of injection and was followed by an elevation of plasma corticosterone. Hormone release is related to the PAF dose infused, the lowest effective PAF concentration was 1 nmol. The stimulatory effect of PAF on ACTH and beta-endorphin secretion was strongly decreased in rats previously treated with purified anti-rat corticotropin-releasing factor (CRF) antibody. These results, associated with the in vitro demonstration that PAF increases CRF release from incubated rat median eminence, strongly support the hypothesis that the stimulatory action of PAF on the secretion of HPA axis products is mediated at least partly, by stimulating hypothalamic CRF release.(ABSTRACT TRUNCATED AT 250 WORDS)

Abstract Prostaglandin E(2), (PGE(2)) is involved in the luteinizing hormone-releasing hormone-stimulated luteinizing hormone surge in female rats and may act via specific membrane receptors. The following studies were performed to determine whether there were any changes in the hypothalamic PGE(2) binding and/or PGE(2) content which were specific to proestrus and not to the rest of the estrous cycle. Groups of female Wistar rats were sacrificed at 3-h intervals throughout the estrous cycle to determine both the circadian and circaestral changes in the hypothalamic PGE(2) content and [(3)H]PGE(2) binding. The hypothalamic PGE(2) content was maximal at 1700 h on each of the 4 consecutive days of the estrous cycle but was independent of the stage of the cycle. [(3)H]PGE(2) binding also displayed a circadian rhythm; the lowest binding occurred near the circadian peak of PGE(2), suggesting that the PGE(2) binding sites were occupied by endogenous PGE(2). Since such circadian rhythms were not observed in the hypothalamus of male rats, they may be under the control of ovarian steroids. Also, since PGE(2) binding and the PGE(2) content both exhibit a diurnal pattern independent of the day of the cycle, there may be changes in the PGE(2) receptor-mediated process coupled to an adenylyl cyclase which could explain the luteinizing hormone surge in proestrus.

AbstractProstaglandin E2, (PGE2) is involved in the luteinizing hormone‐releasing hormone‐stimulated luteinizing hormone surge in female rats and may act via specific membrane receptors. The following studies were performed to determine whether there were any changes in the hypothalamic PGE2 binding and/or PGE2 content which were specific to proestrus and not to the rest of the estrous cycle. Groups of female Wistar rats were sacrificed at 3‐h intervals throughout the estrous cycle to determine both the circadian and circaestral changes in the hypothalamic PGE2 content and [3H]PGE2 binding. The hypothalamic PGE2 content was maximal at 1700 h on each of the 4 consecutive days of the estrous cycle but was independent of the stage of the cycle. [3H]PGE2 binding also displayed a circadian rhythm; the lowest binding occurred near the circadian peak of PGE2, suggesting that the PGE2 binding sites were occupied by endogenous PGE2. Since such circadian rhythms were not observed in the hypothalamus of male rats, they may be under the control of ovarian steroids. Also, since PGE2 binding and the PGE2 content both exhibit a diurnal pattern independent of the day of the cycle, there may be changes in the PGE2 receptor‐mediated process coupled to an adenylyl cyclase which could explain the luteinizing hormone surge in proestrus.

Le but de cette étude est la recherche des conditions optimales de sensibilisation du radio-immunodosage. Nous avons développé un traitement informatique qui permet, à partir des concentrations et des caractéristiques des réactifs mis en jeu, de modéliser la courbe dose-réponse. La sensibilité est définie soit par la limite de détection, c'est-à-dire la concentration montrant un signal statistiquement différent de celui obtenu en l'absence de compétiteur, soit par la limite de précision, c'est-à-dire la concentration montrant un coefficient de précision acceptable dans le profil de précision. Les résultats démontrent qu'en fonction de l'affinité de l'anticorps et de l'activité spécifique du traceur l'amélioration des performances suppose un choix optimal des concentrations (activité totale pour le traceur et dilution pour l'anticorps). Le programme développé permet d'analyser l'ensemble de ces facteurs.

Among the different biochemical pathways which have been suggested to play a role in the control of prolactin (Prl) release from anterior pituitaries, arachidonate and its metabolites have been proposed to be involved in the process of Prl release. In this study we investigated the contribution of arachidonate metabolites to both basal and TRH-stimulated Prl release from perifused lactotrophs in culture (derived from pituitary glands of lactating female rats), which exhibit a high sustained release of Prl in absence of inhibitory input. Inhibition of the general oxidative metabolism of arachidonate by 10(-5) M ETYA or of the arachidonate lipoxygenase metabolism by 10(-5) M NDGA decreased basal Prl release to 45 +/- 10% (n = 3) and 36 +/- 4% (n = 6) of the control release, respectively. Indomethacin, an inhibitor of the cyclooxygenase pathway, was without effect. Of the lipoxygenase metabolites tested at 10(-6) M only 15-HPETE and 15-HETE induced Prl release. 15-HETE elicited prolactin release in a concentration dependent manner with a maximal effect at 10(-6) M (10.72 +/- 3 ng/ml vs control 5.1 +/- 0.8 ng/ml, n = 3). The quantity of Prl release induced by TRH was markedly decreased in the presence of NDGA. However, the fraction of Prl release elicited by TRH, calculated as a percentage of the amount of Prl released prior to TRH application, was similar under control conditions, and in the presence of NDGA. In contrast, inhibition of the protein kinases A and G by H8 (10(-5) M) failed to alter basal Prl release but inhibited the effect of TRH by 58 +/- 6% (n = 3). These data suggest that in absence of inhibitory inputs the high sustained release of Prl observed in cultures of lactotrophs derived from lactating female rats depends on the availability of lipoxygenase metabolites, and that the blockade of lipoxygenase reduces the absolute amount of Prl released by TRH without suppressing the ability of TRH to stimulate Prl release.

The castration of adult rats four weeks before experimentation did not alter either the basal production of prostaglandin (PG) E2 (intact rats 1157 +/- 160 pg/mg protein, castrated rats 1093 +/- 90 pg/mg protein) or the A 23187-induced production of PGE2 (1591 +/- 209 or 1701 +/- 286 pg/mg protein respectively) or that of leucotriene (LT) C4 (474 +/- 33, 389 +/- 39 pg/mg protein). Castration significantly reduced the absolute amounts of luteinizing hormone-releasing hormone (LHRH) released under basal conditions (594 +/- 56 pg/mg protein to 34% of intact controls) and after A 23187 stimulation (to 28% of controls). The LHRH released by the median eminence (ME) of castrated rats in the presence of PGE2 (10(-6) M), LTC4 (10(-8) M), norepinephrine (NE) (10(-5) M) or dopamine (DA) (10(-5) M and 10(-4) M) was significantly lower than the LHRH released by intact animals in the presence of these factors. However the relative values for LHRH release (e.g. as % of controls) indicated that the degree of stimulation was identical in intact and castrated rats (2-3 times). These data suggest that the absence of gonadal steroids resulting from long-term castration does not block the stimulatory action of eicosanoids or catecholamines on the release of LHRH by the ME of adult male rats in vitro. Furthermore, castration does not interfere with the biosynthesis of PGE2 and LTC4.

Rabbits were immunized with [Ac-D-beta-Nal1-, D-p-Cl-Phe2, D-Phe3, D-Arg6, Phe7, D-Ala10]LHRH (BIM 21009) coupled to bovine serum albumin using bis-diazotized benzidine. The best antiserum had an affinity of 5. 10(-10) M and a specificity directed against the C-terminal part of the molecule. The antiserum was not affected by native LHRH but reacted to some extent with detergents. Assay of free-peptide plasma after gel filtration on Ultrogel AcA 34 showed apparent immunoreactivity associated with albumin and lipoproteins. The sensitivity of direct assay was 0.4 ng/ml. Measurements of BIM 21009 after s.c. injection in rats showed the resistance of the peptide to elimination. The specificity of the determinations in plasma were checked by High Performance Liquid Chromatography.